Table 2. Characteristics * by Randomization Group.
| Characteristics | First Randomization Event (n = 49) N (%) | Mupirocin/Hexachlorophene Group (n = 21) N (%) | Placebo Group (n = 28) N (%) |
|---|---|---|---|
| Demographics | |||
| Age, years | 44 (IQR 37,49) | 41 (IQR 34,47) | 46 (IQR 38,52) |
| Gender, male | 48 (98%) | 20 (95%) | 28 (100%) |
| Ethnicity | |||
| Caucasian | 24 (49%) | 9 (43%) | 15 (53%) |
| African-American | 22 (44%) | 10 (47%) | 12 (43%) |
| Other | 3 (6%) | 2 (9%) | 1 (4%) |
| Social Habits | |||
| Illicit drug use 1 , 2 | 2 (4%) | 2 (10%) | 0 (0%) |
| Clinical Site | |||
| Site 1 | 15 (31%) | 7 (33%) | 8 (29%) |
| Site 2 | 18 (37%) | 8 (38%) | 10 (36%) |
| Site 3 | 14 (28%) | 5 (24%) | 9 (32%) |
| Site 4 | 2 (4%) | 1 (5%) | 1 (3%) |
| Medical History | |||
| Diabetes | 3 (6%) | 1 (5%) | 2 (7%) |
| Chronic skin disease | 6 (12%) | 2 (10%) | 4 (14%) |
| History of SSTI 2 | 19 (39%) | 8 (38%) | 11 (39%) |
| History of MRSA infection | 14 (29%) | 7 (33%) | 7 (25%) |
| Hospitalization 3 | 9 (18%) | 3 (14%) | 6 (21%) |
| ER/acute care clinic 2 , 3 | 0 (0%) | 0 (0%) | 0 (0%) |
| Current use of TMP-SMX | 3 (6%) | 1 (5%) | 2 (7%) |
| HIV History | |||
| Duration of HIV, years | 9.1 (IQR 2.3,20) | 7.7 (IQR 2.3,17) | 9.4 (IQR 2.2,20) |
| Current CD4 count, cells/mm 3 | 494 (IQR 390,660) | 494 (IQR 312,695) | 500 (IQR 424,618) |
| CD4 by category | |||
| <350 cells/mm 3 | 9 (18%) | 7 (33%) | 2 (7%) |
| 350–499 | 16 (33%) | 4 (19%) | 12 (43%) |
| ≥500 | 24 (49%) | 10 (48%) | 14 (50%) |
| Currently receiving HAART 2 | 32 (65%) | 14 (67%) | 18 (64%) |
| Current HIV viral load detectable (≥50 copies/mL) | 20 (41%) | 10 (48%) | 10 (36%) |
*Characteristics at the time of randomization
**Statistical testing were conducted using Wilcoxon-Mann-Whitney test for continuous variables, Chi-square test for categorical variables cells greater than five, Fisher’s exact test for categorical variables cells less than five
1 Within 6 months prior to study enrollment
2 All data represent n = 49, except there were missing data for the following variables: illicit drug use (n = 1), history of SSTI (n = 1), ER visit (n = 9), and current HAART use (n = 1).
3 Within 12 months prior to study enrollment